Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Bb Healthcare Trust Plc LSE:BBH London Ordinary Share GB00BZCNLL95 RED ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.50 0.86% 175.50 174.50 175.00 175.50 172.00 172.50 1,306,839 16:35:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 2.7 0.3 0.0 - 858

Bb Healthcare Share Discussion Threads

Showing 26 to 42 of 100 messages
Chat Pages: 4  3  2  1
DateSubjectAuthorDiscuss
01/12/2016
06:54
Article and video: Http://citywire.co.uk/money/bb-healthcare-we-wont-buy-price-gougers/a975223?ref=citywire-money-latest-news-list
jonwig
30/11/2016
08:44
Friday 2nd isn't it, Molby? £150m vs target £200m - seems private investors weren't over keen here.
jonwig
26/11/2016
13:49
Thanks Jonwig, you give me a degree of comfort but also a new worry, the Trump effect. Recently one of the doomsters said that the Trump effect might well emulate the Ronald Regan era in which the market rose as he took office, peaked in April and then fell by 20% by September. I think I will buy, expect to top up in late 2017 and then wait 5 years for the reward.
daveofdevon
26/11/2016
12:11
Hi, Dave - you caught me just as I was off to cook lunch, so quickly ... Healthcare, pharma might get a boost from Trump (ie. non-Clinton) and the Trump rally still has some way to go I think. Paying divis out of capital, share buybacks and annual redemption should limit the downside. Track record of managers in an existing fund looks good. Charges not excessive and no performance fee. Like you I'm very cautious at present with lots of cash and short-dated gilts, but I shall apply for some. By the way I haven't trawled through the prospectus!!
jonwig
16/11/2016
07:01
jaws - I didn't know they'd tried before. Thanks.
jonwig
16/11/2016
06:41
They tried last year twice to pull IPO at last minute.there is few other which trades at discount like BIOG. will try to get more discout link later when I can.
jaws6
16/11/2016
06:37
Cheers - I've copied that to the header. I'm inclined to invest here, there's a lot of attractive features in the way it's set up.
jonwig
15/11/2016
23:14
Thanks for setting the thread up, jonwig. Here's the prospectus for further details... HTTP://www.bbhealthcaretrust.com/index.php?eID=tx_nawsecuredl&u=12&g=1&t=1479337412&hash=00e341cc10485c5e0362086233d8e7bd351c4ae6&file=fileadmin/user_upload/files/bbhealthcaretrust/Prospectus.pdf
strollingmolby
14/11/2016
16:30
This isn't a sector I know much about. Would welcome any views. Discount and redemption policy looks useful. My broker's deadline is 28 Nov. Minimum 1,000 shs @ 100p.
jonwig
14/11/2016
16:29
. Http://www.bbhealthcaretrust.com . IPO to close at end of month. £200m at 100p. From the factsheet: • To provide Shareholders with capital growth and income over the long term, through investment in listed or quoted global healthcare companies • Specific return objectives are: (i) to beat the total return of the MSCI World Healthcare Index (in sterling) on a rolling 3 year period (the index total return including dividends reinvested on a net basis); and (ii) to seek to generate a double-digit total shareholder return per annum over a rolling 3 year period • Target total dividend in the first financial period is 3.5p per ordinary share (to be paid mostly out of capital); target annual dividend in subsequent financial years set at 3.5% of preceding financial year end NAV (to be paid mostly out of capital and in two equal instalments) Summary investment policy • BB Healthcare intends to invest in a concentrated portfolio of listed or quoted equities in the global healthcare industry (maximum of 35 holdings) • The investable universe for BB Healthcare is the global healthcare industry including companies within industries such as pharmaceuticals, biotechnology, medical devices and equipment, healthcare insurers and facility operators, information technology (where the product or service supports, supplies or services the delivery of healthcare), drug retail, consumer healthcare and distribution • There will be no restrictions on the constituents of BB Healthcare’s portfolio by index benchmark, geography, market capitalisation or healthcare industry sub-sector. BB Healthcare will not seek to replicate the benchmark index in constructing its portfolio. Link to Prospectus: HTTP://www.bbhealthcaretrust.com/index.php?eID=tx_nawsecuredl&u=12&g=1&t=1479337412&hash=00e341cc10485c5e0362086233d8e7bd351c4ae6&file=fileadmin/user_upload/files/bbhealthcaretrust/Prospectus.pdf Significant Holdings (total 253,911,268 shares after second issue): Heartwood W M ....... 10,813,202 4.2% Erich Hunziker ...... 10,000,000 3.9% Schroders ............ 8,064,100 3.2% Whale Holding AG ..... 3,525,000 1.5% Net asset values (monthly): 02/12/16 ... 98.28p 03/01/17 .. 103.55p 28/02/17 .. 112.3p 31/03/17 .. 110.6p 30/04/17 .. 111.4p 31/05/17 .. 110.2p
jonwig
12/7/2006
15:01
.S. Stocks Drop on Genentech Shortfall; Microsoft Declines July 12 (Bloomberg) -- U.S. stocks fell as a sales report from Genentech Inc. increased concern that earnings will trail analyst estimates. Genentech, the world's second-largest biotechnology company, dropped after revenue from colon-cancer treatment Avastin fell short of investor expectations. Brunswick Corp. declined after the boat maker said 2006 profit will decline. ``The concern really is: Can earnings growth continue?'' said Larry Peruzzi, a senior equity trader at Boston Co. in Boston. Investors are ``very cautious.'' The Standard and Poor's 500 Index lost 1.84, or 0.1 percent, to 1270.68 at 10:17 a.m. in New York. The Dow Jones Industrial Average fell 15.77, or 0.1 percent, to 11,119. The Nasdaq Composite Index dropped 9.16, or 0.4 percent, to 2119.70, dragged down by Microsoft Corp. Genentech's sales, along with shortfalls from Alcoa Inc. and Lucent Technologies Inc., raised concern that economic and earnings growth may slow. Investors are also wary higher interest rates may be cutting into profits. Analysts expect S&P 500 companies to report 12.3 percent growth in earnings for the April-to-June period, based on a survey by Thomson Financial. The Federal Reserve has raised interest rates 17 times over two years to 5.25 percent. Genentech's Miss Genentech lost $2.26 to $81.80. U.S. sales of Avastin totaled $423 million during the second quarter. That was less than what investors were expecting, according to Cowen & Co. analyst Eric Schmidt. Profit rose 79 percent as doctor's prescribed more of the company's medicines. Deutsche Bank AG and Prudential Equity Group Inc. both downgraded the company's stock. . . Genentech and Brunswick became the latest companies to disappoint investors. Alcoa, the world's largest aluminum producer, said second-quarter profit fell short of analyst estimates and record earnings aren't sustainable. Lucent said sales and profit missed analyst estimates.
energyi
09/1/2006
21:14
Symb Company Name===== $Price Weight DNA- Genentech Inc.. : $44.00 32.19% AMGN Amgen Inc...... : $64.48 27.42% BIIB Biogen Idec Inc : $26.95. 9.94% GILD Gilead Sciences : $16.00. 6.17% CHIR Chiron Corp.... : $16.00. 5.12% GENZ Genzyme Corp... : $14.00. 4.59% ==== Sub-Totals===== : ...... 85.43% Others: Applera - Appl.Biosystems ABI 18.00 2.56% MedImmune Inc........... MEDI 15.00 2.55% Sepracor Inc............ SEPR. 6.00 1.95% Millennium Pharmaceutic. MLNM 12.00 1.48% Shire Pharmaceuticals.. SHPGY. 6.83 1.41% ICOS Corp............... ICOS. 4.00 1.07% Affymetrix Inc.......... AFFX. 4.00 0.92% Qlt Inc................. QLTI. 5.00 0.82% Human Genome Sciences... HGSI. 8.00 0.67% Alkermes Inc............ ALKS. 4.00 0.41% Applera - Celera Genomics CRA. 4.00 0.40% Enzon Inc............... ENZN. 3.00 0.33%
energyi
24/10/2005
20:40
I'm short DNA thru Puts
energyi
13/8/2005
07:38
WAIT ON BIOTECHS DESPITE RECENT STRENGTH by Bruce Zaro August 12, 2005 With investor optimism toward the stock market returning, I felt it appropriate to write a follow-up to my most recent article, ¡§Semiconductors Confirming Economic Strength,¡¨ by highlighting another high-octane sector of the market. Biotechnology stocks capture investors¡¦ hopes and fears like no other group, save Internet stocks. As people search for the company that will provide the cure for cancer, AID, etc. and it¡¦s no shock that the cycle of promise and disappointment in this sector can result in a $1.13 stock that runs up to $3.50 Tuesday and settles back to $1.20 by Friday. Indeed, the biotech sector as a whole thus far in 2005 has shown a first quarter performance of negative 9.9% while the second quarter rebounded to show a 12.5% gain. Love ¡¥em and hate ¡¥em all in the same year: that¡¦s the biotech group. Because this sector can be so volatile, I believe it is possible to be a little bit late to the party and still catch significant percentage moves in individual biotech issues. Thus, I tend to hold biotech stocks in our portfolios only when they clearly show signs of sponsorship and particularly when they¡¦re exhibiting such strength from oversold levels. And since this volatile sector can provide buying opportunities and significant profit taking opportunities in short order, it is wisest for most investors to steer toward the large, liquid biotech names such as Gilead, Amgen and Genentech while avoiding the flash-in-the-pan types like Entremed and Ariad, despite their momentary allure. Further, my investment management style is firmly based on the premise that when investing, market conditions are most important in determining when to act, followed by the sector¡¦s condition and only lastly by individual stock selection. This classic ¡§top-down¡¨ approach to technical analysis is crucial since studies have shown that market and sector conditions typically account for more than 75% of a stock¡¦s movement, with only a fraction of share price movement actually coming from the company¡¦s fundamentals itself. Because I so highly value market and sector conditions when analyzing what to buy, perhaps a look at whether the Biotech sector currently makes sense is in order. While the market is currently on the offensive, from a supply and demand standpoint it is in relatively poor field position and the rally from the May lows is getting tired. Recently, there have been some early signs that the summer dog days are starting to set in. Because we reach such posture in front of the often-troubling months of September and October, I am expecting any pullback we might see in those months to provide an attractive entry point. Because the Biotech sector relative strength is strong and getting stronger, it will be one of the groups I¡¦ll have my eye on in coming weeks. As can be seen in the chart below, the sector bullish percentage recently exceeded its previous top at 50 (most recent column of Xs, which mark rising trends in Point and Figure analysis): @: http://www.financialsense.com/fsu/editorials/2005/0812.html
energyi
20/7/2005
18:36
why vernalis fallin??
latifs100
20/7/2005
18:23
amex biotech ... See www.AMEX.com for more details. Components of AMEX Biotech Index (BTK). Symbol, Name. ... IBH=, AMEX BIOTECH HOLDERS. ICX=, AMEX THESTREET.COM E-COMMERCE INDEX
energyi
18/7/2005
20:55
Amgen earnings coming out tomorrow
energyi
Chat Pages: 4  3  2  1
ADVFN Advertorial
Your Recent History
LSE
BBH
Bb Healthc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201203 05:41:29